Latest Regulatory Developments News

Coast Entertainment reports a robust first half of FY26 with significant growth in ticket sales and visitation, driven by new attractions and strong promotional campaigns. The Group also strengthens its financial position amid ongoing economic challenges.

AdAlta Limited has aligned its AdCella manufacturing strategy with new US FDA guidelines, made a significant milestone payment to Shanghai Cell Therapy Group, and secured an additional R&D tax rebate, marking key progress in its cellular immunotherapy pipeline.

The Calmer Co. International Limited has reported its highest ever monthly sales of $910,767 in December 2025, driven by strong wholesale growth and expanding US market presence.

Osmond Resources is fast-tracking development of its Orión EU Critical Minerals Project, with initial drilling confirming high-grade titanium, zircon, and rare earth elements. The company aims to complete a maiden Mineral Resource Estimate and Scoping Study by mid-2026.

Elsight Limited has secured a US$460,000 purchase order from a U.S. public safety customer, marking a significant commercial milestone amid accelerating FAA regulations for drone operations beyond visual line of sight.

The FDA’s recent ruling classifying traditionally prepared kava beverages as food under U.S. law clears a major regulatory hurdle for The Calmer Co, accelerating its growth on Amazon and strengthening its U.S. expansion strategy.

Saluda Medical has received CE certification for its EVA™ Sensing Technology, enabling commercialisation in Europe and recognition in Australia following prior FDA approval. This milestone sets the stage for a broader rollout of its personalised spinal cord stimulation therapy in early 2026.

Seven West Media shareholders have overwhelmingly approved the proposed acquisition by Southern Cross Media Group, clearing a major hurdle ahead of final court approval.

Seven West Media shareholders have overwhelmingly approved the proposed acquisition by Southern Cross Media Group, clearing a major hurdle ahead of final court approval.

Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.

African Gold secures ASX waiver allowing cancellation of options without shareholder approval as part of Montage Gold acquisition scheme. This regulatory step smooths the path for the proposed takeover and option restructuring.

Robex Resources has amended its acquisition agreement with Predictive Discovery, lowering the exchange ratio and postponing the shareholder meeting to December 30, 2025. The Robex Board unanimously recommends approval, supported by updated fairness opinions.